These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29775668)

  • 1. Current approaches to the discovery of novel inhaled medicines.
    Strong P; Ito K; Murray J; Rapeport G
    Drug Discov Today; 2018 Oct; 23(10):1705-1717. PubMed ID: 29775668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in inhaled product development and opportunities for open innovation.
    Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
    Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis.
    Eriksson J; Sjögren E; Thörn H; Rubin K; Bäckman P; Lennernäs H
    Eur J Pharm Biopharm; 2018 Mar; 124():1-12. PubMed ID: 29191716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaling medicines: delivering drugs to the body through the lungs.
    Patton JS; Byron PR
    Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The particle has landed--characterizing the fate of inhaled pharmaceuticals.
    Patton JS; Brain JD; Davies LA; Fiegel J; Gumbleton M; Kim KJ; Sakagami M; Vanbever R; Ehrhardt C
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S71-87. PubMed ID: 21133802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
    Hu X; Yang FF; Liao YH
    Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options.
    Aungst BJ
    J Pharm Sci; 2017 Apr; 106(4):921-929. PubMed ID: 27986598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids.
    Rohatagi S; Rhodes GR; Chaikin P
    J Clin Pharmacol; 1999 Jul; 39(7):661-3. PubMed ID: 10392319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary delivery of therapeutic compounds for treating CNS disorders.
    Noymer P; Biondi S; Myers D; Cassella J
    Ther Deliv; 2011 Sep; 2(9):1125-40. PubMed ID: 22833910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug metabolism in the lungs: opportunities for optimising inhaled medicines.
    Enlo-Scott Z; Bäckström E; Mudway I; Forbes B
    Expert Opin Drug Metab Toxicol; 2021 May; 17(5):611-625. PubMed ID: 33759677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs.
    Tronde A; Nordén B; Marchner H; Wendel AK; Lennernäs H; Bengtsson UH
    J Pharm Sci; 2003 Jun; 92(6):1216-33. PubMed ID: 12761811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities.
    Rinderknecht CH; Ning M; Wu C; Wilson MS; Gampe C
    Expert Opin Drug Discov; 2024 Apr; 19(4):493-506. PubMed ID: 38407117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.
    Ehrhardt C
    Pharm Res; 2017 Dec; 34(12):2451-2453. PubMed ID: 29147818
    [No Abstract]   [Full Text] [Related]  

  • 17. Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements.
    Rangaraj N; Pailla SR; Sampathi S
    Pulm Pharmacol Ther; 2019 Feb; 54():1-21. PubMed ID: 30447295
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulmonary drug delivery: medicines for inhalation.
    Henning A; Hein S; Schneider M; Bur M; Lehr CM
    Handb Exp Pharmacol; 2010; (197):171-92. PubMed ID: 20217530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled nanoparticles--a current review.
    Yang W; Peters JI; Williams RO
    Int J Pharm; 2008 May; 356(1-2):239-47. PubMed ID: 18358652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.